简 EN 繁
简 EN 繁

Please enter the information you want to find

Hot key words：
Hyaluronidase xxx
News Center News Center

News Center

2025.12.10

​Shanghai Bao Pharma Successfully Listed on the Hong Kong Stock Exchange, Ushering in a New Era of Recombinant Biologics

View details
​Shanghai Bao Pharma Successfully Listed on the Hong Kong Stock Exchange, Ushering in a New Era of Recombinant Biologics
[News] BaoPharma's KJ015 Injection (Subcutaneous) Receives Clinical Trial Approval from the NMPA
2025.02.13

[News] BaoPharma's KJ015 Injection (Subcutaneous) Receives Clinical Trial Approval from the NMPA

View details
[News] Bao Pharma Completes Pharmaceutical Excipient Registration for Hyaluronidase
2024.11.21

[News] Bao Pharma Completes Pharmaceutical Excipient Registration for Hyaluronidase

View details
[News] KJ103 (Recombinant Immunoglobulin G-degrading Enzyme Ricefidase for injection) Designated as a Breakthrough Therapy
2024.11.20

[News] KJ103 (Recombinant Immunoglobulin G-degrading Enzyme Ricefidase for injection) Designated as a Breakthrough Therapy

View details
[News] Bao Pharma's "KJ103 for Injection" (Recombinant Immunoglobulin G-degrading Enzyme Ricefidase) Receives Clinical Trial Approval from NMPA
2024.08.22

[News] Bao Pharma's "KJ103 for Injection" (Recombinant Immunoglobulin G-degrading Enzyme Ricefidase) Receives Clinical Trial Approval from NMPA

View details
1234